Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AC Immune SA    ACIU   CH0329023102

AC IMMUNE SA (ACIU)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
11.45(c) 10.82(c) 10.75(c) 10.98(c) 10.61(c) Last
155 840 132 825 72 062 231 626 76 464 Volume
-1.29% -5.50% -0.65% +2.14% -3.37% Change
More quotes
Financials ($)
Sales 2017 17,8 M
EBIT 2017 -26,6 M
Net income 2017 -30,7 M
Finance 2017 118 M
Yield 2017 -
Sales 2018 25,0 M
EBIT 2018 -38,9 M
Net income 2018 -41,4 M
Finance 2018 80,9 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 28,2x
EV / Sales2018 21,5x
Capitalization 620 M
More Financials
Company
AC Immune SA is a clinical stage biopharmaceutical company, which engages in leveraging two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.It's... 
Sector
Biotechnology & Medical Research
Calendar
11/16 | 07:40amPresentation
More about the company
Surperformance© ratings of AC Immune SA
Trading Rating : Investor Rating :
More Ratings
Latest news on AC IMMUNE SA
11/02 AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into P..
10/24 AC Immune to Present at Two Investor Conferences and Provide Scientific Updat..
10/03 AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundati..
09/12 Ac immune completes recruitment for low-dose cohort in world's first clinica..
08/22 AC IMMUNE : Discovers next-generation antibodies focused on neurodegenerative di..
08/09 Ac immune reports second quarter 2017 financial results
07/10 Ac immune provides seven updates on its pipeline and technology at the alzhei..
06/28 Ac immune announces results of annual general meeting
05/22 Ac immune and essex bio-technology announce research collaboration for neurod..
05/11 AC IMMUNE : Reports first quarter 2017 financial results
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/13 AC Immune misses by $0.03
08/22 AC Immune discovers two new antibodies targeted to neurodegenerative diseases..
08/18 Now Is The Perfect Time To Diversify Internationally
08/09 AC Immune reports Q2 results
08/04 Value Investment Stock Selections Using Forensic Analysis - August
Chart AC IMMUNE SA
Duration : Period :
AC Immune SA Technical Analysis Chart | ACIU | CH0329023102 | 4-Traders
Technical analysis trends AC IMMUNE SA
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 21,5 $
Spread / Average Target 96%
EPS Revisions
Managers
NameTitle
Andrea Pfeifer CEO, Director & Head-Investor Relations
Martin Velasco Chairman
Jörg Hornstein Chief Financial Officer
Andreas Muhs Chief Scientific Officer
Detlev H. Riesner Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AC IMMUNE SA-17.18%620
CELLTRION, INC.--.--%24 494
INCYTE CORPORATION4.96%22 471
IQVIA HOLDINGS INC36.54%22 070
LONZA GROUP56.09%19 543
ALNYLAM PHARMACEUTICALS, INC.236.40%12 427